What AI says about Veristat
Since Jul 5Updated Nov 12, 2026Based on 1,446 AI answers
Reviewed by Dimitry Apollonsky
Mentioned in · Public index
1%
of AI answers about Veristat and its rivals · since Jul 5
Based on 1,446 AI answers
- ChatGPT1%
- Google AI Mode1%
How often AI mentions Veristat
of AI answers about Veristat and its rivals
Track your brand free to see 13 weeks of history.
Use the left and right arrow keys to read each date.
Sep 14OctNov 2
- · ChatGPT switched to GPT-6 Luna
Markets where AI mentions Veristat
All marketsChatGPTGoogle AI Mode
Topics where AI mentions Veristat
TopicMentioned in · on this topicRank
- Most mentionedMentioned in
- I need a decentralized clinical trial platform that supports eConsent and home health visits.on this questionMedable is the most-mentioned brand14%
Excerpts where Veristat appeared in the AI's answer
ChatGPTOct 14, 2026, ChatGPT Veristat — integrates eConsent, remote monitoring, telehealth, and protocol-compliant at-home nursing into decentralized trial strategies.
Google AI ModeJul 12, 2026, Google AI Mode Veristat: Focuses on highly customizable, integrated solutions, particularly for complex trials, with the ability to manage at-home visits and remote, site-based activities.
- What's the best modern CRO for a startup running its first clinical trial?on this questionMedpace is the most-mentioned brand3%
Veristat in AI answers
1 of 2
I need a decentralized clinical trial platform that supports eConsent and home health visits.
ChatGPTChatGPT· Oct 14, 2026
Veristat — integrates eConsent, remote monitoring, telehealth, and protocol-compliant at-home nursing into decentralized trial strategies.
Google AI ModeGoogle AI Mode· Jul 12, 2026
Veristat: Focuses on highly customizable, integrated solutions, particularly for complex trials, with the ability to manage at-home visits and remote, site-based activities.
Sites AI cites
The page AI cites most often when it mentions Veristat
Brands AI mentions
Mentioned in
- IQVIA19%
- Medable11%
- ICON plc5%
- Science 374%
- Thread Research4%

